Zhongyuan Xiehe announced that the VUM02 injection from its wholly-owned subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. was used in phase I/II clinical trials of grade II to grade IV acute graft-versus-host disease where hormone treatment failed. The first phase I multiple dose subjects completed enrolment administration on July 17, 2026. As of May 2026, the project invested a total of 8.308,900 yuan in R&D. Drugs need to complete clinical trials, apply for marketing approval, and be reviewed and approved before they can be marketed. There is uncertainty.

Zhongyuan Xiehe announced that the VUM02 injection from its wholly-owned subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. was used in phase I/II clinical trials of grade II to grade IV acute graft-versus-host disease where hormone treatment failed. The first phase I multiple dose subjects completed enrolment administration on July 17, 2026. As of May 2026, the project invested a total of 8.308,900 yuan in R&D. Drugs need to complete clinical trials, apply for marketing approval, and be reviewed and approved before they can be marketed. There is uncertainty.